(Q38475978)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

review article

1 reference

title

Latest approaches for the treatment of obesity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

V Margaret Jackson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Danna M Breen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jean-Philippe Fortin

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Alice Liou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A Katrina Loomis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Marie-Laure Rives

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Bhavik Shah

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Philip A Carpino

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

12 May 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

825-839

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25967138%20AND%20SRC:MED&resulttype=core&format=json

Global obesity: trends, risk factors and policy implications

8 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Results of Roux-en-Y gastric bypass in morbidly obese vs superobese patients: similar body weight loss, correction of comorbidities, and improvement of quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Trends in Weight Regain Following Roux-en-Y Gastric Bypass (RYGB) Bariatric Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Bariatric surgery: risks and rewards

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Investigational drugs in Phase II clinical trials for the treatment of obesity: implications for future development of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Neuropsychiatric adverse effects of centrally acting antiobesity drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Cardiovascular risk-benefit profile of sibutramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Long-term drug treatment for obesity: a systematic and clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The MC4 receptor and control of appetite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Central nervous control of energy and glucose balance: focus on the central melanocortin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Cannabinoids, opioids and eating behavior: the molecular face of hedonism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Reward, dopamine and the control of food intake: implications for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Metabolic and hedonic drives in the neural control of appetite: who is the boss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Genetics of body-weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Genetic strategies to understand physiological pathways regulating body weight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Monogenic obesity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Common variants near MC4R are associated with fat mass, weight and risk of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Genome-wide association yields new sequence variants at seven loci that associate with measures of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Six new loci associated with body mass index highlight a neuronal influence on body weight regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Genetic studies of body mass index yield new insights for obesity biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Congenital leptin deficiency is associated with severe early-onset obesity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Leptin and the regulation of body weight in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Structure, production and signaling of leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Physiological response to long-term peripheral and central leptin infusion in lean and obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Obesity and leptin resistance: distinguishing cause from effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effects of recombinant leptin therapy in a child with congenital leptin deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Leptin treatment: facts and expectations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Role of leptin in the neuroendocrine response to fasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Low dose leptin administration reverses effects of sustained weight-reduction on energy expenditure and circulating concentrations of thyroid hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

"Weighing in" on synergy: preclinical research on neurohormonal anti-obesity combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Region-specific leptin resistance within the hypothalamus of diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

New pharmacological perspectives for the leptin receptor in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Endospanins regulate a postinternalization step of the leptin receptor endocytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Endospanin 1 silencing in the hypothalamic arcuate nucleus contributes to sustained weight loss of high fat diet obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Anti-obesity phenotypic screening looking to increase OBR cell surface expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

20 years of leptin: connecting leptin signaling to biological function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The role of SOCS-3 in leptin signaling and leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Pharmacological inhibition of protein tyrosine phosphatase 1B: a promising strategy for the treatment of obesity and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Hypothalamic tanycytes are an ERK-gated conduit for leptin into the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Endoplasmic reticulum stress plays a central role in development of leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Endoplasmic reticulum stress induces leptin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Targeting endoplasmic reticulum stress in metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Melanocortin 4 receptors reciprocally regulate sympathetic and parasympathetic preganglionic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Regulation of glucose tolerance and sympathetic activity by MC4R signaling in the lateral hypothalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

A genetically specified connectomics approach applied to long-range feeding regulatory circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

G-protein-independent coupling of MC4R to Kir7.1 in hypothalamic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Pharmacological Chaperones Restore Function to MC4R Mutants Responsible for Severe Early-Onset Obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Rescue of defective MC4R cell-surface expression and signaling by a novel pharmacoperone Ipsen 17.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Ipsen 5i is a Novel Potent Pharmacoperone for Intracellularly Retained Melanocortin-4 Receptor Mutants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Obesity-linked variants of melanocortin-4 receptor are misfolded in the endoplasmic reticulum and can be rescued to the cell surface by a chemical chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Melanocortin-4 receptor modulators for the treatment of obesity: a patent analysis (2008-2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Discovery that a melanocortin regulates sexual functions in male and female humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Brain effects of melanocortins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Melanocortin signalling and the regulation of blood pressure in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Investigation of safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of a long-acting α-MSH analog in healthy overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effects of AgRP inhibition on energy balance and metabolism in rodent models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Melanocortin-4 receptor expression in a vago-vagal circuitry involved in postprandial functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

An intrinsic gut leptin-melanocortin pathway modulates intestinal microsomal triglyceride transfer protein and lipid absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Opioid receptor mu 1 gene, fat intake and obesity in adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Hypothalamic POMC neurons promote cannabinoid-induced feeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Food reward: brain substrates of wanting and liking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The neurobiological underpinnings of obesity and binge eating: a rationale for adopting the food addiction model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Nucleus accumbens opioid, GABAergic, and dopaminergic modulation of palatable food motivation: Contrasting effects revealed by a progressive ratio study in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Endogenous opioids and feeding behavior: a 30-year historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effects of long-term therapy with naltrexone on body weight in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Cellular localization of proglucagon/glucagon-like peptide I messenger RNAs in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Distribution of glucagon-like peptide 1-immunopositive neurons in human caudal medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not contr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Fibroblast growth factor 21 corrects obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Novel locus including FGF21 is associated with dietary macronutrient intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

LY2405319, an Engineered FGF21 Variant, Improves the Metabolic Status of Diabetic Monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/β-Klotho bispecific protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The fasting polypeptide FGF21 can enter brain from blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The future role of gut hormones in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The relationship between gut microbiota and weight gain in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Modulation of the gut microbiota by nutrients with prebiotic and probiotic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Gut microbiota from twins discordant for obesity modulate metabolism in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Gut microbiomes of Malawian twin pairs discordant for kwashiorkor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Branched-chain amino acids in metabolic signalling and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effects of rectal administration of taurocholic acid on glucagon-like peptide-1 and peptide YY secretion in healthy humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Expression of the short-chain fatty acid receptor, GPR43, in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Gastric stimulation for weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Pharmacological management of obesity: an endocrine Society clinical practice guideline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

New drug targets for the treatment of obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966

Functional properties of leptin receptor isoforms: internalization and degradation of leptin and ligand-induced receptor downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1044966